Company Overview
Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Why Investors Should Care
Generates a return on equity of 17.4%, reflecting efficient use of shareholder capital.
Revenue has grown at a 955.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $30.41M (+955.1% YoY); net profit $-219.34M.
- Trailing 12 Months Year-on-year growth — revenue +106.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 955.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 955.14% |
| 1 Year: | 106.50% |
Stock Price Performance
| 1 Year: | +51.28% |
| 6 Months: | +36.09% |
| 3 Months: | +43.41% |
| 1 Month: | +43.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross4d ago
- RSI (14)70.93 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 955.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FRNM Freenome, Inc. PHARMA | 15.99 | -7.72 | $1.72B | 0.00% | -47.90% | 17.36% | 955.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -121.95K | -196.13K | -255.96K | -193.20K | -856.16K | -858.83K | -941.33K |
| Net Income | 102.88K | 981.48K | 678.55K | 754.85K | 144.63K | -51.75K | -114.94K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 2.88M | 30.41M |
| Cost of Revenue | 2.56M | 1.94M |
| Gross Profit | 318.00K | 28.46M |
| Operating Expenses | 292.29M | 251.93M |
| Operating Income | -291.97M | -223.47M |
| EBITDA | -258.55M | -192.17M |
| Interest Expense | 0 | 2.82M |
| Pretax Income | -274.42M | -219.34M |
| Tax Provision | - | - |
| Net Income | -274.42M | -219.34M |
| Diluted EPS | -2.65 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 551.92M | 507.05M |
| Current Assets | - | 252.60M | 226.49M |
| Cash & Equivalents | - | 67.05M | 78.56M |
| Inventory | - | - | - |
| Receivables | - | 1.66M | 1.31M |
| Total Liabilities | - | 1.61B | 1.77B |
| Current Liabilities | - | 41.88M | 40.53M |
| Long Term Debt | - | - | 102.50M |
| Total Debt | - | 206.52M | 311.62M |
| Total Equity | 0 | -1.06B | -1.26B |
| Shares Outstanding | - | 106.10M | 106.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -196.37M | -110.67M |
| Investing Cash Flow | -52.81M | 21.38M |
| Financing Cash Flow | 263.99M | 100.76M |
| Capital Expenditure | -60.41M | -21.05M |
| Free Cash Flow | -256.78M | -131.72M |
| Net Change in Cash | 14.81M | 11.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 11.0% | 93.6% |
| Operating Margin % | -10,130.9% | -734.9% |
| Net Margin % | -9,521.9% | -721.3% |
| ROE % | 26.0% | 17.4% |
| ROCE % | -57.2% | -47.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FRNM
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5mNmRvNHI3Z002UlhxQ2dHYXUzekdGY0oxN3JXUlE2VHpBc2Rra2xNMFh3bi1YRlUtdERzTkpaZUdIN0xBeFlEc0NXa3oxbnRq?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Investors withdraw billions from stock market funds - The Times
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQWXE2NTkwaWs3QmMzUUdiNVNJSWpsSmhnQ1AtMGl3RHpyZ3pfZm1QZ3NDZFlacV9VdWlHZy1fRkRRc2NYZ015VjdqMTlqbXFvRUpFOVdKN3E1Mjk3ODdnTm1zMVVQZzFZd0NFY3B5YW44M2pfdUh6RDVCVFFmakNiZjBZMlpLS2NIV3c5Qn…
Rep. Van Orden highlights his House vote to block members from stock trading while they're in Congress - wizmnews.com
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPbWxqTGN2ODJ5U3dvb0g2T1k5QnVUaGdPUnQ3SVlqSVE2cFhjODdIUnZFb1dxT3JTdXE2ajA2WXg0ZFlVXzlGV3lRZWdkQ2pVZWg2SkpLc3NTZ2hmWjB6V1FPS0JkdFRiWUt4TnFJTk5EejMzTVpvdEE5LVlXYkw2VlMwekIxWF9vd1dobm…
Freenome CEO Elliott Aaron Matthew Forfeits 71,920 Shares at $15.25 Each (NASDAQ: FRNM) - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQU2Nob3ZiNU5jZ01UbEpBTDdESjdNMnZ4VnNkcFAyOUNfdk9ST2NoS1hzQ2s5cHdjbmZVZHJUTnhvcEs2bk1HenpJTVhfTHpsUHVjc3dyQUFjeVhPZ3cwRGlUU1RpQlJOOHd5OGZ0V1hfZC1IRDV3RGh2eHE2VVN5dnpjQlQtRXVpMDRIem…
No ETFs Required: How a 64-Year-Old Built a $5,700 Monthly Paycheck From Five Dividend Stocks - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQS2JZYVg1MEl4WDRZNkNwRl9Ld2hsOXdjVEdLY1RaSl9nSlRXWGZPSlNxQ0xsWWVTdWFwbERPcnI4aG04dlh3dWcwUGRodGpNdEVlMTMxVWc1NlRjcHJRYjB1MVFPc1VKTHotNGYyNEdELVNBWUNRalhIaTV5UWlheUFNUWc5cE12dlZDdW…
Wall Street banks reap windfall from stock and debt sales - Axios
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE9XX0VOSDFVN21xSzhPY0Q1aXZ6SFdwbjVkT2xyZVNtNGRBeE14dm00UlZTY2U1a1pWX2hTVERYSkE4TEJIcmNLWWROT0hBMzdodVRSd2RsUUhDbENqTFh5Y0VCaFp0ODlxOWE0YmV2SzNWT3lq?oc=5" target="_blank">Wall Street…
FRNM — Frequently Asked Questions
What is the current share price of Freenome, Inc. (FRNM)?
As of 2026-09-19 21:16 PDT, Freenome, Inc. (FRNM) trades at $15.99 on NasdaqCM. Its 52-week range is $9.99 to $16.90.
What is the market capitalisation of FRNM?
Freenome, Inc. (FRNM) has a market capitalisation of $1.72B on NasdaqCM.
What is the P/E ratio of FRNM?
FRNM trades at a trailing price-to-earnings (P/E) ratio of -7.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.30.
What is the return on equity (ROE) of FRNM?
FRNM has a return on equity (ROE) of 17.36%. Its return on capital employed (ROCE) is -47.90%.
Is FRNM a good stock to buy?
This page provides a data-driven analysis of Freenome, Inc. (FRNM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.